20
Participants
Start Date
November 30, 2012
Primary Completion Date
March 31, 2014
Study Completion Date
March 31, 2014
RVX000222
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
Placebo, RVX000222
capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
Baker IDI Heart and Diabetes Institute 75 Commercial Road,, Melbourne
Collaborators (1)
Baker Heart and Diabetes Institute
OTHER
Nucleus Network Ltd
OTHER
Resverlogix Corp
INDUSTRY